



## Ovarian Cancer: Recent Advances in Research and Clinical Therapy

Guest Editor:

### Dr. Mandi Murph

Department of Pharmaceutical  
and Biomedical Sciences, The  
University of Georgia College of  
Pharmacy, Athens, GA 30602, USA

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### Message from the Guest Editor

Epithelial ovarian carcinoma remains a lethal gynecological malignancy among women across the globe. Although this malignancy is very responsive to therapy, the late-stage disease lacks definitive curability. Modern clinical treatment methods have increased survival rates, but drug resistance and refractory disease in recurrent patients continue to challenge oncologists. Translational research and clinical trials provide hope for the future. In addition, new areas of science may provide revolutionary insights into the drivers of inherited disease and adaptation to drug resistance. Whether immunotherapy will play a prominent role in treatment is still under investigation, as well as the origin of cancer stem cells. This issue will highlight some of the clinical and research advances that sustain hope.

Dr. Mandi Murph  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)